A Day Up For NeuBase Therapeutics, Inc.

Fri, Feb 10, 2023 at 07:13 PM

NeuBase Therapeutics, Inc. (NBSE:NASDAQ) jumped higher at $0.33, representing a gain of 26.9%. On Fri, Feb 10, 2023, NBSE:NASDAQ touched a New 2-Week High of $0.33. From Fri, Jan 27, 2023, the stock recorded 50.00% Up Days and 36.36% Green Days

About NeuBase Therapeutics, Inc. (NBSE:NASDAQ)

Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.

Top 10 Gainers:

Allied Healthcare Products, Inc. (AHPI:NASDAQ), 400%
Vallon Pharmaceuticals Inc. (VLON:NASDAQ), 72.57%
SeqLL Inc. (SQL:NASDAQ), 57.14%
Expion360 Inc. (XPON:NASDAQ), 55.56%
FLJ Group Limited (FLJ:NASDAQ), 44.95%
Hillstream BioPharma Inc. (HILS:NASDAQ), 34.75%
Oriental Culture Holding LTD (OCG:NASDAQ), 33.35%
Oscar Health Inc. Class A (OSCR:NYSE), 30.26%
VistaGen Therapeutics, Inc. (VTGN:NASDAQ), 27.19%
NeuBase Therapeutics, Inc. (NBSE:NASDAQ), 26.92%